Castle Biosciences (CSTL) stock forecast for 2022
Last update: 06-24-2022, 9:14Sector: Healthcare
The share price of Castle Biosciences, Inc. (CSTL) now
What analysts predict:: $48.29
52-week high/low: $78.92 / $15.58
50/200 Day Moving Average: $21.69 / $42.93
This figure corresponds to the average price over the previous 50/200 days. For Castle Biosciences stocks, the 50-day moving average is the resistance level today.
For Castle Biosciences stocks, the 200-day moving average is the resistance level today.
Are you interested in Castle Biosciences stocks and want to buy them, or are they already in your portfolio? If yes, then on this page you will find useful information about the dynamics of the Castle Biosciences stock price in 2022. How much will one Castle Biosciences share be worth in 2022?
Is it worth taking profit / loss on Castle Biosciences stock now or waiting? What are analysts' forecasts for Castle Biosciences stock?
We forecast Castle Biosciences stock performance using neural networks based on historical data on Castle Biosciences stocks. Also, when forecasting, technical analysis tools are used, world geopolitical and news factors are taken into account.
The Castle Biosciences stock prediction results are shown below and presented as a graph, table and text information.
Castle Biosciences stock forecasts are adjusted once a day based on the closing price of the previous trading day.
The minimum target price for Castle Biosciences analysts is $48.29.
Today 200 Day Moving Average is the resistance level (42.93 $).
50 Day Moving Average is the resistance level (21.69 $).
Historical and forecast chart of Castle Biosciences stock
The chart below shows the historical price of Castle Biosciences stock and a prediction chart for the next year. For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast, and Weighted Average Best Forecast. Detailed values for the Castle Biosciences stock price can be found in the table below.
Castle Biosciences (CSTL) Forecast for 2022
Castle Biosciences information and performance
Castle of Biological Sciences, Inc., a commercial stage dermatological cancer, develops and commercializes diagnostic and prognostic tests for cancers. Its flagship product is DecisionDx-Melanoma, a Multiple Gene Expression Profile (GEP) test for identifying Stage I and II patients at high risk of metastasis, based on biological information from 31 genes in their tumor tissue. The company also offers the DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis in patients with uveal melanoma, a rare eye cancer; and two late-stage proprietary products that address squamous cell skin cancer and suspicious pigmented lesions, which are highly clinical indications for dermatological cancer. It offers testing services through physicians, physician assistants and nurse practitioners. The company was founded in 2007 and is headquartered in Friendswood, Texas.
Castle Biosciences Address
820 S FRIENDSWOOD DRIVE, SUITE 201, FRIENDSWOOD, TX, US
Market Capitalization: 470 858 000 $
Market capitalization is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of shares in the company outstanding by the market price of one share.
EBITDA: 5 935 000 $
EBITDA is earnings before interest, income tax and depreciation of assets.
PE Ratio: None
P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit
PEG Ratio: None
Price/earnings to growth
Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.
Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.
EPS shows how much of the net profit is accounted for by the common share.
Quarterly Earnings Growth YOY: -0.926
Quarterly Revenue Growth YOY: 0.177
Trailing PE: -
Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.
Forward PE: -
Forward P/E uses projections of future earnings instead of final numbers.
EV To Revenue: 1.323
Enterprise Value (EV) /Revenue
EV To EBITDA: 11562.57
The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).
Shares Outstanding: 26260900
Number of issued ordinary shares
Shares Float: N/A
Number of freely tradable shares
Shares Short Prior Month: N/A
Shares Short Prior Month - the number of shares in short positions in the last month.
Short Ratio: N/A
Percent Insiders: N/A
Percent Institutions: N/A
Castle Biosciences price target for 2021 by month
Target values for the price of one Castle Biosciences share for Jul 2022.
Pessimistic target level: 21.46
Optimistic target level: 25.38
Target values for the price of one Castle Biosciences share for Aug 2022.
Pessimistic target level: 21.35
Optimistic target level: 25.67
Target values for the price of one Castle Biosciences share for Sep 2022.
Pessimistic target level: 22.57
Optimistic target level: 25.27
Target values for the price of one Castle Biosciences share for Oct 2022.
Pessimistic target level: 23.21
Optimistic target level: 26.51
Target values for the price of one Castle Biosciences share for Nov 2022.
Pessimistic target level: 23.92
Optimistic target level: 28.80
Target values for the price of one Castle Biosciences share for Dec 2022.
Pessimistic target level: 28.12
Optimistic target level: 30.81
Related stocks from Healthcare sector
All forecast data on the site are provided for informational purposes of using neural forecasting tools in the financial market and are not a call to action and, moreover, are not trading signals. When using the forecast data, the investor assumes all financial risks. The pandaforecast.com portal is not responsible for the loss of your money in the stock market as a result of using the information contained on the site.